FY2029 EPS Estimates for Medicus Pharma Reduced by Analyst

Medicus Pharma Ltd (NASDAQ:MDCX) – Research analysts at Brookline Capital Markets cut their FY2029 earnings per share (EPS) estimates for shares of Medicus Pharma in a research report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of $0.65 per share for the year, down from their previous forecast of $0.73. The consensus estimate for Medicus Pharma’s current full-year earnings is ($0.73) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s FY2030 earnings at $1.22 EPS.

Several other brokerages also recently issued reports on MDCX. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday. Roth Capital initiated coverage on Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Wednesday, July 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medicus Pharma has a consensus rating of “Hold” and an average price target of $9.00.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $0.26 on Monday. Medicus Pharma has a 52 week low of $0.24 and a 52 week high of $3.05. The company’s 50 day moving average price is $0.37 and its two-hundred day moving average price is $0.52. The company has a market capitalization of $16.64 million, a P/E ratio of -0.11 and a beta of 0.12.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08).

Institutional Trading of Medicus Pharma

A number of institutional investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new position in Medicus Pharma during the fourth quarter worth $2,771,000. Private Advisor Group LLC increased its stake in Medicus Pharma by 36.8% in the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after buying an additional 64,560 shares during the last quarter. Jane Street Group LLC acquired a new stake in Medicus Pharma in the 4th quarter valued at $92,000. Wilmington Savings Fund Society FSB increased its stake in Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares during the last quarter. Finally, May Hill Capital LLC lifted its position in Medicus Pharma by 100.0% during the 4th quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock worth $55,000 after buying an additional 17,811 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.